Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, issued the following open lette...
Amicus Therapeutics (Nasdaq: FOLD) announced that it has entered into a License Agreement (Agreement) with Teva Pharmaceuticals USA, Inc. and Teva Pharmace...
AtomVie Global Radiopharma (AtomVie), a leading radiopharmaceutical Contract Development and Manufacturing Organization (CDMO), has entered into an agreeme...
Exelixis, Inc. (Nasdaq: EXEL) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the companies have entered i...
Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlan...
Sanofi announces that the company has entered into negotiations with CD&R for the potential sale of a 50% controlling stake in Opella, its cons...
Symbiosis acquires a 20,000 sq/ft building in Stirling, UK, to house new high-tech medicines manufacturing capacity, financed by £1...
Global pharma major Lupin Limited (Lupin) announced that its South African subsidiary, Pharma Dynamics, has acquired nine brands along with their associa...
Genentech will acquire Regor's next-generation CDK inhibitors for an upfront payment of $850 million in cash. Regor ...
In a year when metabolic diseases have drawn major investor interest, the newest player has big-name backing, a sizable war chest and veteran leadership. ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the completion of the acquisition of CN201 from Curon Biopharmaceutical ...
Telix Pharmaceuticals Limited announced an agreement to acquire RLS (USA) Inc. (RLS), America's only Joint Commission-accredited radiopharmacy network sp...
Singular Genomics Systems, a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and cli...
Strengthens Rare Disease segment as largest driver of future growth, adding approximately $105 million in 2024 revenue on a pro forma basis Adds two d...
© 2024 Biopharma Boardroom. All Rights Reserved.
